Filana Therapeutics
FLNA
26 hedge funds and large institutions have $4.07M invested in Filana Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0.06% more ownership
Funds ownership: 19.41% → 19.47% (+0.06%)
4% less funds holding
Funds holding: 27 → 26 (-1)
6% less capital invested
Capital invested by funds: $4.33M → $4.07M (-$255K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$112K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$21.8K |
| 3 |
JP Morgan Chase
New York
|
+$15.6K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$13.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$51K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47.5K |
| 3 |
BlackRock
New York
|
-$41.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$27K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$14K |
FLNA Hedge Fund Activity: Q2 2019 in Review
26 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2019, worth a combined $4.07M — down 5.9% from $4.33M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FLNA and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $112K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $51K sold.
- 26 institutional investors held Filana Therapeutics (FLNA) as of Q2 2019, down from 27 in Q1 2019.
- Funds reported $4.07M of Filana Therapeutics stock for Q2 2019, down 5.9% quarter-over-quarter.
- 3 funds opened new Filana Therapeutics positions in Q2 2019 and 4 closed out, a net change of -1 holder.
- The largest Filana Therapeutics buyer in Q2 2019 was Renaissance Technologies, an estimated $112K added.
- The largest Filana Therapeutics seller in Q2 2019 was Acadian Asset Management, an estimated $51K sold.
Based on aggregated 13F filings for Q2 2019.